Finance

Novonesis sales miss market view as growth stalls in agriculture, tech segments

Published by Global Banking & Finance Review

Posted on February 25, 2026

2 min read

· Last updated: April 2, 2026

Add as preferred source on Google
Spirax manufacturing facility showcasing growth in UK sales - Global Banking & Finance Review
Image of Spirax's manufacturing operations emphasizes the company's optimistic sales growth forecast for the second half of the year, reflecting strong performance in the finance sector.
Global Banking & Finance Awards 2026 — Call for Entries

Feb 25 (Reuters) - Danish biosolutions company Novonesis reported weaker-than-expected organic sales growth for the fourth quarter on Wednesday, held back by flat revenue in the Agriculture, Energy &

Novonesis Reports Lower Q4 Sales Amidst Sector Challenges

Novonesis Q4 Sales Performance

Feb 25 (Reuters) - Danish biosolutions company Novonesis reported weaker-than-expected organic sales growth for the fourth quarter on Wednesday, held back by flat revenue in the Agriculture, Energy & Tech business.

Impact of Feed Enzyme Alliance Acquisition

While the unit's euro sales were positively impacted by the 2025 acquisition of the remaining stake in Feed Enzyme Alliance, this boost was offset by currency headwinds elsewhere, Novonesis said in a statement, another European chemicals group grappling with strong home currencies eroding reported numbers.

Key Financial Details

KEY DETAILS

* Novonesis delivered quarterly organic growth of 4%,against 5.2% seen in a company-provided consensus. * The biggest miss to analysts' expectations came within thePlanetary Health segment, where Agriculture, Energy & Tech sawno growth in euros versus 7% expected by analysts. * Negative timing in the agriculture segment and a toughcomparison period in tech hindered growth, despite positivedevelopment in the energy business area, the company said in apresentation. * "We delivered double digit growth in bioenergy in Q4, andwe're already seeing a strong start to 2026," CEO Ester Baigettold Reuters. * Quarterly adjusted earnings before interest, taxes,depreciation and amortization (EBITDA) were 364.6 million euros($429.9 million), 10 million euros below consensus. * For 2026, Novonesis guides for organic sales growthbetween 5-7% and a higher adjusted EBITDA margin of 37-38%,including currency headwinds of about 50 bps year-on-year. * Jyske Bank analysts said that late‑year signs of consumersoftness were hardly encouraging after a strong year. * Novonesis' shares have lost around 20% of their valuesince peaking in June 2025. They were down less than 2% at 1135GMT.

($1 = 0.8480 euros)

(Reporting by Izabela Niemiec in Gdansk, editing by Milla Nissi-Prussak)

Key Takeaways

  • Q4 organic sales growth landed below consensus, reflecting a softer finish to the year.
  • Planetary Health underperformed as Agriculture, Energy & Tech posted flat growth versus expectations.
  • Adjusted EBITDA came in slightly under analysts’ estimates, pressured by FX.
  • For 2026, management guides 5–7% organic growth and a 37–38% adjusted EBITDA margin, assuming currency headwinds.
  • The 2025 Feed Enzyme Alliance deal aided euro-reported sales but broader FX pressures offset the benefit.

References

Frequently Asked Questions

What is the main topic?
Novonesis’ fourth‑quarter results missed sales expectations as growth stalled in its Agriculture, Energy & Tech unit, prompting a cautious 2026 outlook for growth and margins.
Why did Agriculture, Energy & Tech underperform?
The unit saw flat growth versus expectations. While euro‑reported sales were helped by the 2025 Feed Enzyme Alliance acquisition, currency headwinds and softness elsewhere offset the boost.
What guidance did Novonesis provide for 2026?
Management targets 5–7% organic sales growth and a 37–38% adjusted EBITDA margin, factoring in continued currency headwinds and execution on pricing and synergy initiatives.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category